Malaria drug combo under microscope: safety first
NCT ID NCT07470424
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety and dosing, not to treat malaria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- piperaquine, pyronaridine, and artesunate
- What this could lead to
- If successful, this study could help doctors understand how to combine these malaria drugs more safely and effectively.
- What could go wrong
- This is a very early, small study in 24 healthy people, not patients. It only looks at drug levels and safety, not whether the drugs cure malaria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Therapeutic Unit, Faculty of Tropical Medicine
Bangkok, Bangkok, 10400, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth